US 11129818
Topical roflumilast formulation having improved delivery and plasma half life
granted A61KA61K31/44A61K45/06
Quick answer
US patent 11129818 (Topical roflumilast formulation having improved delivery and plasma half life) held by ARCUTIS BIOTHERAPEUTICS, INC. expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ARCUTIS BIOTHERAPEUTICS, INC.
- Grant date
- Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/44, A61K45/06, A61K47/06, A61K47/10